AliveDx, FDA

AliveDx announces US FDA 510 submission for MosaiQ AiPlex® Connective Tissue Diseases multiplex microarray

Published on 08/07/2025 at 18:06 | prnewswire.co.uk

AliveDx Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom United States of America

and connect with us on LinkedIn and X.

©AliveDx Suisse SA. 2025. The AliveDx logo, AliveDx, MosaiQ, MosaiQ AiPlex, and LumiQ are trademarks or registered trademarks of AliveDx group companies in various jurisdictions. Menus and capabilities are subject to change. Not all methods may be available in all territories. Subject to regulatory clearance. 

1. Nathalie Conrad et al. Lancet 2023; 401: 1878–90 *ACR: American College of Rheumatology. EULAR: European Alliance of Associations for Rheumatology.
2. Aringer M et al. Ann Rheum Dis. 2019;78(9):1151-9.
3. Shiboski CH et al. Arthritis Rheumatol. 2017;69(1):35-45.
4. van den Hoogen F et al. Arthritis Rheum. 2013;65(11):2737-47.
5. Lundberg IE et al. Arthritis Rheumatol. 2017;69(12):2271-82.
6. Aletaha D et al. Arthritis Rheum. 2010;62(9):2569-81. 

Logo - https://mma.prnewswire.com/media/2657402/AliveDx_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/alivedx-announces-us-fda-510k-submission-for-mosaiq-aiplex-connective-tissue-diseases-ctdplus-multiplex-microarray-302419688.html

en | boerse | 67951406 |